Solitary plasmacytoma of bone and asymptomatic multiple myeloma

Slides:



Advertisements
Similar presentations
Multiple Myeloma Definition:
Advertisements

Awareness Is Everything By Karis M. Blalock. Hypothesis Why is it important to understand what Multiple Myeloma is?
Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome by Bart.
1.Defining Plasma cell disorders/Multiple Myeloma 2.Identification of different plasma cell disorders. 3.Diagnosis and workup for plasma cell disorders/Multiple.
Hairy Cell Leukemia Variant Has Similar Survival to Classical Disease Despite Poorer Responses to Initial Therapy: A 30-Year Experience from Memorial Sloan.
How I treat HHV8/KSHV-related diseases in posttransplant patients by Giovanni Riva, Mario Luppi, Patrizia Barozzi, Fabio Forghieri, and Leonardo Potenza.
New criteria for response assessment: role of minimal residual disease in multiple myeloma by Bruno Paiva, Jacques J. M. van Dongen, and Alberto Orfao.
Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)‏ by Antonio Palumbo,
Minimal Residual Disease (MRD) in Multiple Myeloma
by Angela Dispenzieri, A. Keith Stewart, Asher Chanan-Khan, S
Yale University School of Medicine
Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)‏ by Antonio Palumbo,
by Robert A. Kyle, Morie A. Gertz, Philip R. Greipp, Thomas E
A Prospective Randomized Trial of Buffy Coat Versus CD34-Selected Autologous Bone Marrow Support in High-Risk Breast Cancer Patients Receiving High-Dose.
How I treat multiple myeloma in younger patients
Multiple Myeloma: Interleukin-15 Antagonizes Bone Morphogenetic Protein-Induced Apoptosis and Growth Inhibition. by Magne Rekvig, Anne-Tove Brenne, Torstein.
Finding a diamond in the (mouse is) rough
Telomerase and telomere length in multiple myeloma: correlations with disease heterogeneity, cytogenetic status, and overall survival by Kai-Da Wu, Lisa.
Gupta V, Tallman MS, Weisdorf DJ
by Nataliya Melnyk, and Jonathan Harrison
Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma by Shaji K. Kumar, Betsy LaPlant,
BTK inhibition in myeloma: targeting the seed and the soil
Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion.
How I treat elderly patients with myeloma
Nonmyeloablative conditioning for relapsed follicular lymphoma
A young patient with multiple myeloma
Symptomatic and Incidental Venous Thromboembolic Disease Are Both Associated With Mortality In Patients With Prostate Cancer by Shruti Chaturvedi, Surbhi.
Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma.
Multiple myeloma (MM) & related disorders
Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report by Antonio Palumbo, Sara.
The role of complete response in multiple myeloma
Autologous Transplantation Therapy for Chronic Myelogenous Leukemia
Long-term outcome of higher-risk MDS patients treated with azacitidine: an update of the GFM compassionate program cohort by Raphael Itzykson, Sylvain.
Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system by.
166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trials by.
Parasternal mass Blood Volume 113(6): February 5, 2009
How we choose factor VIII to treat hemophilia
Relative increase in leukemia-specific DNA in peripheral blood plasma from patients with acute myeloid leukemia and myelodysplasia by Anna Rogers, Youngson.
“Update” on “solitary” plasmacytoma
by Jayesh Mehta Blood Volume 112(2): July 15, 2008
Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma by Rishi K.
by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle
Stage C or not stage C…? by Claire Dearden Blood
by Michael F. Leahy, and J. Harvey Turner
Bone Turnover Biomarkers Are Useful In Monitoring Myeloma Bone Disease and As Early Predictor Biomarkers For Relapse Disease In Multiple Myeloma by Kay.
Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study by Samantha C. Gouw,
Erythroid leukemia evolving from multiple myeloma
Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma by Angela Dispenzieri,
Multiple Myeloma in Serologic Complete Remission after Autologous Stem Cell Transplantation: Impact of Bone Marrow Plasma Cell Assessment by Conventional.
Chronic graft-versus-host disease
Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia by Philip.
Stanley Owen Snyder, MD  Journal of Vascular Surgery 
Oncolytic Virotherapy: A Contest between Apples and Oranges
by Elizabeth C. Neil, and Lisa M. DeAngelis
Overall Survival (OS) of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus.
by Wendy Lim, Sara K. Vesely, and James N. George
Treatment versus Transplant for Challenging Hematologic Disorders
Treatment options for relapsed and refractory multiple myeloma
Survival based on V gene mutation status and CD38 expression among B-CLL patients who stratify to the Rai intermediate risk category. Survival based on.
Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables by Andrew W. Roberts, Shuo Ma, Thomas J.
The natural history of respiratory syncytial virus infection in cancer and transplant patients: implications for management by Elias J. Anaissie, Tahsine.
by Robert A. Kyle, and S. Vincent Rajkumar
Time-dependent survival estimation in post–polycythemia vera myelofibrosis. Time-dependent survival estimation in post–polycythemia vera myelofibrosis.
Secretory status of monoclonal immunoglobulin is related to the outcome of patients with myeloma: a retrospective study by Xiao-Qi Qin, Gang An, Zeng-Jun.
Suggested algorithm for bone marrow biopsy and skeletal imaging in patients with monoclonal gammopathy of undetermined significance. #Mayo Clinic Risk.
CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML by Claire M. Lucas, Laura J. Scott, Natasha Carmell,
A Novel Risk Assessment Model to Predict Venous Thromboembolism (VTE) in Cancer Inpatients: The Canclot Score by Dana E. Angelini, M. Todd Greene, Julie.
Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis by.
Balancing bleeding in brain metastases
Cold agglutinin disease
Presentation transcript:

Solitary plasmacytoma of bone and asymptomatic multiple myeloma by Meletios A. Dimopoulos, Lia A. Moulopoulos, Alice Maniatis, and Raymond Alexanian Blood Volume 96(6):2037-2044 September 15, 2000 ©2000 by American Society of Hematology

Remission and survival in solitary bone plasmacytoma Remission and survival in solitary bone plasmacytoma.The panel on the left shows the remission time in 61 patients with solitary plasmacytoma of bone treated at the MD Anderson Cancer Center, according to disappearance and persistence of myeloma protein or ... Remission and survival in solitary bone plasmacytoma.The panel on the left shows the remission time in 61 patients with solitary plasmacytoma of bone treated at the MD Anderson Cancer Center, according to disappearance and persistence of myeloma protein or nonsecretory myeloma. The panel on the right shows cause-specific survival after radiotherapy in the same groups of patients. Meletios A. Dimopoulos et al. Blood 2000;96:2037-2044 ©2000 by American Society of Hematology

Progression of asymptomatic myeloma Progression of asymptomatic myeloma.The panel on the left shows the variable times to disease progression in 123 asymptomatic patients with multiple myeloma at the MD Anderson Cancer Center, according to risk status defined by the presence of 0, 1, or 2 or ... Progression of asymptomatic myeloma.The panel on the left shows the variable times to disease progression in 123 asymptomatic patients with multiple myeloma at the MD Anderson Cancer Center, according to risk status defined by the presence of 0, 1, or 2 or more of the following abnormalities: monoclonal protein level above 30 g/L, IgA myeloma protein type, and urinary protein level above 50 mg/day on Bence Jones assessment (P < .01). The panel on the right shows the variable times to disease progression in 43 asymptomatic patients considered at intermediate risk on the basis of magnetic resonance imaging results (P < .01). Meletios A. Dimopoulos et al. Blood 2000;96:2037-2044 ©2000 by American Society of Hematology